The tumor suppressor liver kinase B1 (LKB1, encoded by *Stk11*) is a bioenergetic sensor that controls cell metabolism and growth^[@R5]^. To define the role of LKB1 in T~reg~ cells, we crossed mice with *lox*P-flanked *Stk11* alleles (*Stk11*^fl/fl^) with *Foxp3*^YFP-Cre^ (*Foxp3*^Cre^) mice^[@R6]^ to specifically delete *Stk11* in T~reg~ cells (designated *Foxp3*^Cre^*Stk11*^fl/fl^) ([Extended Data Fig. 1a](#F5){ref-type="fig"}). Compared with *Foxp3*^Cre^ controls (designated as WT), *Foxp3*^Cre^*Stk11*^fl/fl^ mice had a significantly shorter lifespan ([Fig. 1a](#F1){ref-type="fig"}) and lower body weight ([Fig. 1b](#F1){ref-type="fig"}), and manifested a reduced body size, skin ulceration and crusting of ears and eyelids ([Fig. 1c](#F1){ref-type="fig"}). Moreover, the mutant mice had splenomegaly and lymphadenopathy ([Fig. 1d](#F1){ref-type="fig"}) and infiltration of immune cells in multiple organs ([Fig. 1e](#F1){ref-type="fig"}). Interestingly, despite largely normal morphology of the colon and cecum in *Foxp3*^Cre^*Stk11*^fl/fl^ mice ([Extended Data Fig. 1b](#F5){ref-type="fig"}), these organs had notable accumulation of interepithelial mucosal mast cells (ieMMCs)^[@R7]^ ([Extended Data Fig. 1c](#F5){ref-type="fig"}). The development of a fatal inflammatory disease in *Foxp3*^Cre^*Stk11*^fl/fl^ mice suggests a crucial role of LKB1 in T~reg~ cells.

Among serum cytokines, IL-4 and IL-5 were markedly elevated in *Foxp3*^Cre^*Stk11*^fl/fl^ mice ([Fig. 1f](#F1){ref-type="fig"}). MCP-1, TNF-α and IFN-γ were also increased ([Extended Data Fig. 1d](#F5){ref-type="fig"}). The titers of serum IgE and IgG1 ([Fig. 1g](#F1){ref-type="fig"}) were much higher in *Foxp3*^Cre^*Stk11*^fl/fl^ mice than controls, while IgG2a/c, IgG2b, IgA and IgM levels were modestly upregulated ([Extended Data Fig. 1e](#F5){ref-type="fig"}). Moreover, *Foxp3*^Cre^*Stk11*^fl/fl^ mice had an increased frequency of eosinophils in the spleen and lung ([Extended Data Fig. 1f, g](#F5){ref-type="fig"}), but normal populations of splenic neutrophils and macrophages ([Extended Data Fig. 1h, i](#F5){ref-type="fig"}). Histological analysis revealed markedly increased eosinophils and Ym1^+^ M2 macrophages in the skin of *Foxp3*^Cre^*Stk11*^fl/fl^ mice ([Extended Data Fig. 1j, k](#F5){ref-type="fig"}). Compared to WT controls, T cells in *Foxp3*^Cre^*Stk11*^fl/fl^ mice showed the memory/effector phenotype (CD44^hi^CD62L^lo^) ([Extended Data Fig. 2a](#F6){ref-type="fig"}), with a large number of CD4^+^ T cells, including T~reg~ cells, expressing the T~H~2 cytokines IL-4 and IL-5 ([Extended Data Fig. 2b, c](#F6){ref-type="fig"}). IFN-γ and IL-17 expression was also elevated, but to a lesser extent ([Extended Data Fig. 2d, e](#F6){ref-type="fig"}). Moreover, CD4^+^ T cells from the lung and colonic lamina propria of *Foxp3*^Cre^*Stk11*^fl/fl^ mice upregulated IL-4 ([Extended Data Fig. 2f](#F6){ref-type="fig"}). These abnormal type 2 immune responses were observed even in CD4^+^ T cells from young *Foxp3*^Cre^*Stk11*^fl/fl^ mice ([Fig. 1h](#F1){ref-type="fig"} and [Extended Data Fig. 2g](#F6){ref-type="fig"}), while *Foxp3*^Cre^*Stk11*^fl/+^ mice showed normal immune homeostasis (data not shown). These results reveal an excessive T~H~2-dominant inflammatory disorder in *Foxp3*^Cre^*Stk11*^fl/fl^ mice.

The T~reg~ cell compartment was reduced in percentage and cellularity in *Foxp3*^Cre-^*Stk11*^fl/fl^ mice ([Fig. 2a](#F2){ref-type="fig"} and [Extended Data Fig. 3a](#F7){ref-type="fig"}). LKB1-deficient T~reg~ cells showed elevated 5-bromodeoxyuridine (BrdU) incorporation ([Extended Data Fig. 3b](#F7){ref-type="fig"}), but also higher levels of caspase-3 activity ([Fig. 2b](#F2){ref-type="fig"}) and expression of Bim ([Fig. 2c](#F2){ref-type="fig"}). The survival defects were observed in LKB1-deficient T~reg~ cells from the mixed bone marrow (BM) chimeras ([Fig. 2d](#F2){ref-type="fig"} and [Extended Data Fig. 3c, d](#F7){ref-type="fig"}), indicating cell-intrinsic effects. Interestingly, *Foxp3*^Cre^*Stk11*^fl/fl^ mice at 2 weeks old had a largely normal proportion of T~reg~ cells ([Extended Data Fig. 3e](#F7){ref-type="fig"}) with normal expression of Bim ([Extended Data Fig. 3f](#F7){ref-type="fig"}). Nonetheless, activation of T cells, infiltrations of immune cells into the lung, and elevation of serum IgE were appreciable in these mice ([Extended Data Fig. 3g--i](#F7){ref-type="fig"}). Depletion of Bim (encoded by *Bcl2l11*) in LKB1-deficient T~reg~ cells substantially restored T~reg~ cell cellularity ([Extended Data Fig. 3j](#F7){ref-type="fig"}), but *Foxp3*^Cre^*Stk11*^fl/fl^*Bcl2l11*^fl/fl^ mice still had elevated frequencies of CD44^hi^CD62L^lo^ ([Extended Data Fig. 3k](#F7){ref-type="fig"}) and IL-4-producing CD4^+^ T cells ([Fig. 2e](#F2){ref-type="fig"}), compared with WT or *Foxp3*^Cre^*Bcl2l11*^fl/fl^ mice ([Extended Data Fig. 3l, m](#F7){ref-type="fig"}). These results identify important roles of LKB1 in mediating both T~reg~ cell survival and function.

The regulatory function is closely associated with signature molecules expressed by T~reg~ cells^[@R1],[@R2]^. The negative co-receptor PD-1 and TNFR superfamily proteins GITR and OX40 were markedly elevated on LKB1-deficient T~reg~ cells from *Foxp3*^Cre^*Stk11*^fl/fl^ mice ([Extended Data Fig. 4a](#F8){ref-type="fig"}) and mixed BM chimeras ([Fig. 2f](#F2){ref-type="fig"}), indicating cell-autonomous effects. In contrast, WT and LKB1-deficient T~reg~ cells had largely comparable or slightly altered expression of CD62L, CD44 ([Extended Data Fig. 4b](#F8){ref-type="fig"}), GATA3, IRF4, T-bet, RORγt ([Extended Data Fig. 4c](#F8){ref-type="fig"}), Foxp3, ICOS, CTLA-4, and CD25 ([Extended Data Fig. 4d, e](#F8){ref-type="fig"}). The co-receptors PD-1, GITR and OX40 have been implicated in the control of T~reg~ cell function and generation^[@R8]--[@R13]^. To examine whether LKB1 directly regulates these T~reg~ signatures in mature T~reg~ cells, we generated *Foxp3*^GFP-Cre-ERT2^*Stk11*^fl/fl^*Rosa26*^YFP^ mice (designated *Foxp3*^Cre-ERT2^*Stk11*^fl/fl^ mice) to delete *Stk11* in T~reg~ cells upon tamoxifen treatment^[@R14]^ ([Extended Data Fig. 4f](#F8){ref-type="fig"}). Longer duration of LKB1 loss dimished T~reg~ cells ([Extended Data Fig. 4g](#F8){ref-type="fig"}), associated with increased cell death ([Extended Data Fig. 4h](#F8){ref-type="fig"}), while T~reg~ cells with acute deletion of LKB1 maintained intact homeostasis ([Extended Data Fig. 4i](#F8){ref-type="fig"}) and Bim expression ([Fig. 2g](#F2){ref-type="fig"}). In this setting of inflammation-free environment ([Extended Data Fig. 4j, k](#F8){ref-type="fig"}), loss of LKB1 upregulated PD-1, GITR and OX40 ([Fig. 2g](#F2){ref-type="fig"}), without affecting Foxp3, ICOS and CD25 ([Extended Data Fig. 4l](#F8){ref-type="fig"}) or the distribution of resting and activated T~reg~ subsets ([Extended Data Fig. 4m](#F8){ref-type="fig"}). Collectively, LKB1 acts in a cell-autonomous and direct manner to suppress a select group of T~reg~ signature molecules.

Continuous T cell receptor (TCR) signaling fuels T~reg~ cell function in maintaining immune tolerance^[@R15],[@R16]^. Stimulation of T~reg~ cells with anti-CD3 and anti-CD28 (α-CD3-CD28) resulted in LKB1 phosphorylation and modestly increased LKB1 expression ([Fig. 3a](#F3){ref-type="fig"}). mTORC1 and HIF-1α are important effector pathways aberrantly upregulated in LKB1-deficient cancer cells and conventional T cells^[@R17],[@R18]^. Unexpectedly, *Foxp3*^Cre^*Stk11*^fl/fl^ T~reg~ cells had slightly reduced mTORC1 activity under steady state ([Fig. 3b](#F3){ref-type="fig"}) and largely normal phosphorylation of S6, AKT (S473) and FOXO1 upon α-CD3-CD28 stimulation ([Extended Data Fig. 5a, b](#F9){ref-type="fig"}). Additionally, depletion of HIF-1α in LKB1-deficient T~reg~ cells failed to rescue the defective T~reg~ cell homeostasis or the inflammatory disorder ([Extended Data Fig. 5c--e](#F9){ref-type="fig"}). 5′AMP-activated protein kinase (AMPK) is a well-documented substrate of LKB1^[@R5]^, the activation of which was lost in LKB1-deficient T~reg~ cells ([Extended Data Fig. 5f](#F9){ref-type="fig"}). Nonetheless, deletion of AMPKα1 and AMPKα2 in T~reg~ cells did not affect T~reg~ cell proportion or immmune homeostasis ([Fig. 3c](#F3){ref-type="fig"} and [Extended Data Fig. 5g, h](#F9){ref-type="fig"}). Altogether, LKB1 is activated by TCR signaling in T~reg~ cells but functions independently of mTORC1-HIF-1α axis and AMPK signaling.

In the transcriptome of WT and LKB1-deficient T~reg~ cells from the mixed BM chimeras, gene set enrichment analysis (GSEA) showed that LKB1 deficiency impaired gene expression implicated in multiple metabolic pathways ([Extended Data Fig. 6a](#F10){ref-type="fig"}), including tricarboxylic acid (TCA) cycle and mitochondrial protein import ([Extended Data Fig. 6b, c](#F10){ref-type="fig"}). Unbiased metabolomic profiling in activated *Foxp3*^Cre^*Stk11*^fl/fl^ T~reg~ cells ([Extended Data Fig. 6d](#F10){ref-type="fig"} and Extended Data Table 1) revealed a profound reduction of metabolic intermediates associated with mitochondrial function including TCA cycle and fatty acid β-oxidation (FAO), as well as those in purine and pyrimidine metabolism, while metabolites in glycolysis were not uniformly altered ([Fig. 3d](#F3){ref-type="fig"} and [Extended Data Fig. 6e, f](#F10){ref-type="fig"}). Interestingly, histamine was increased in LKB-deficient T~reg~ cells ([Fig. 3e](#F3){ref-type="fig"}). Histidine decarboxylase (HDC), an enzyme to convert histidine to histamine, was increased in LKB1-deficient T~reg~ cells ([Fig. 3f](#F3){ref-type="fig"}). As histamine has been implicated in suppressing T~reg~ cell function^[@R19]^, an increased production of histamine in LKB-deficient T~reg~ cells could contribute to their defects in an autocrine manner. Metabolite set enrichment analysis indicated that LKB1 deficiency in T~reg~ cells downregulated multiple metabolic programs, but upregulated the pathway for biosynthesis of unsaturated fatty acids ([Fig. 3g](#F3){ref-type="fig"}). LKB1-deficient T~reg~ cells had defective mitochondrial fitness, indicated by reduced mitochondrial mass, mitochondrial membrane potential, and reactive oxygen species (ROS) ([Extended Data Fig. 6g](#F10){ref-type="fig"}), associated with diminished intracellular ATP ([Extended Data Fig. 6h](#F10){ref-type="fig"}). LKB1 deletion reduced oxygen consumption rate (OCR) ([Extended Data Fig. 6i](#F10){ref-type="fig"}) without significantly affecting extracellular acidification rate (ECAR) ([Extended Data Fig. 6j](#F10){ref-type="fig"}), further supporting impaired mitochondrial function. Furthermore, LKB1-deficient T~reg~ cells showed a notable accumulation of lipids ([Extended Data Fig. 6k](#F10){ref-type="fig"}), associated with defective FAO ([Extended Data Fig. 6l](#F10){ref-type="fig"}) but normal lipogenesis ([Extended Data Fig. 6m](#F10){ref-type="fig"}). Therefore, LKB1 orchestrates proper metabolic rewiring and mitochondrial function in T~reg~ cells.

We next explored the cellular processes underlying excessive T~H~2 responses in *Foxp3*^Cre^*Stk11*^fl/fl^ mice. Deletion of IL-4 partly rescued T~H~2 responses in *Foxp3*^Cre^*Stk11*^fl/fl^ mice, as indicated by partially mitigated proportions of IL-13- and IL-5-producing CD4^+^ T cells, accumulation of eosinophils and PD-L2^+^ DCs that are associated with T~H~2 responses^[@R20]^, and production of serum IgE and IgG1 ([Extended Data Fig. 7a--e](#F11){ref-type="fig"}). However, T~reg~ cell compartment remained defective in *Foxp3*^Cre^*Stk11*^fl/fl^*Il4*^−/−^ mice, as indicated by a reduced T~reg~ proportion ([Extended Data Fig. 7f](#F11){ref-type="fig"}) and aberrant PD-1, GITR and OX40 expression ([Extended Data Fig. 7g](#F11){ref-type="fig"}). Moreover, these mice had increased proportions of CD44^hi^CD62L^lo^ memory/effector cells and IFN-γ-producing CD4^+^ T cells and extensive inflammation in various organs ([Extended Data Fig. 7h--j](#F11){ref-type="fig"}). Collectively, these results indicate that IL-4 contributes to amplifying T~H~2 responses in *Foxp3*^Cre^*Stk11*^fl/fl^ mice, but is not responsible for the failures in immune tolerance.

Thymic stromal lymphopoietin (TSLP), a key cytokine produced by epithelial cells, polarizes DCs to drive allergic inflammation^[@R21]^. *Foxp3*^Cre^*Stk11*^fl/fl^ mice had elevated production of TSLP in the lung ([Fig. 4a](#F4){ref-type="fig"}), but normal expression of IL-25 and IL-33 ([Extended Data Fig. 8a](#F12){ref-type="fig"}). TSLP upregulated expression of PD-L2^[@R20]^ ([Fig. 4b](#F4){ref-type="fig"}), CD80 and CD86 on DCs ([Extended Data Fig. 8b](#F12){ref-type="fig"}). DCs from *Foxp3*^Cre^*Stk11*^fl/fl^ mice had aberrant upregulation of PD-L2 ([Fig. 4c](#F4){ref-type="fig"}), suggesting that LKB1-deficient T~reg~ cells fail to control maturation of PD-L2^+^ DCs. In support of this notion, WT T~reg~ cells inhibited the induction of PD-L2, CD80 and CD86 on DCs primed with TSLP (TSLP-DCs), whereas LKB1-deficient T~reg~ cells did not ([Fig. 4d](#F4){ref-type="fig"} and [Extended Data Fig. 8c](#F12){ref-type="fig"}). Furthermore, TSLP-DCs polarized the differentiation of naïve CD4^+^ T cells into T~H~2 cells, which was effectively suppressed by WT but not LKB1-deficient T~reg~ cells ([Fig. 4e](#F4){ref-type="fig"} and [Extended Data Fig. 8d](#F12){ref-type="fig"}). In contrast, LKB1-sufficient and -deficient T~reg~ cells were equally capable of suppressing T~H~1 cell differentiation driven by LPS-primed DCs ([Extended Data Fig. 8e, f](#F12){ref-type="fig"}). Therefore, T~reg~ cells require LKB1 to repress maturation of TSLP-DCs and subsequent induction of T~H~2 responses.

To test the physiological relevance of LKB1-mediated regulatory mechanisms in T~H~2 responses, we examined the expression of PD-1, GITR and OX40 on T~reg~ cells from mice challenged with ovalbumin (OVA)-induced allergic airway inflammation. OVA inhalation elicited the expression of these factors on T~reg~ cells in the lung ([Extended Data Fig. 9a](#F13){ref-type="fig"}), but not those in the spleen ([Extended Data Fig. 9b](#F13){ref-type="fig"}). Given the unique and potent roles of PD-1 in T cells for immune modulation and therapy^[@R22]^, we hypothesized that aberrant induction of PD-1 on LKB1-deficient T~reg~ cells disrupts their function in suppressing T~H~2 responses. We tested this hypothesis using gain- and loss-of-function approaches. First, ectopic expression of PD-1 impaired the capability of T~reg~ cells in suppressing T~H~2 cell differentiation ([Extended Data Fig. 9c](#F13){ref-type="fig"}). Second, PD-1 deficiency promoted T~reg~-mediated suppression of T~H~2 responses ([Extended Data Fig. 9d](#F13){ref-type="fig"}). Third, to examine the function of PD-1-deficient T~reg~ cells *in vivo*, we generated mixed BM chimeras using BM cells from T~reg~-deficient Scurfy mice, together with those from WT or *Pdcd1*^−/−^ mice. Scurfy:*Pdcd1*^−/−^ chimeras had reduced proportion of lung and spleen eosinophils ([Extended Data Fig. 9e](#F13){ref-type="fig"}) and concentration of serum IgG1 ([Extended Data Fig. 9f](#F13){ref-type="fig"}), but normal concentration of IgG2a/c ([Extended Data Fig. 9f](#F13){ref-type="fig"}). Finally, blocking PD-1 and its ligands largely reversed the defect of LKB1-deficient T~reg~ cells in suppressing T~H~2 cell differentiation ([Fig. 4f](#F4){ref-type="fig"}). Therefore, LKB1 restrains PD-1 expression as an important mechanism to ensure the functional integrity of T~reg~ cells in repressing T~H~2 responses.

How does LKB1 regulate PD-1 and other T~reg~ signature molecules? Wnt signaling, which is implicated in T~H~2-mediated inflammation^[@R23]^ and T~reg~ cell survival and function^[@R24],[@R25]^, was significantly underrepresented in gene sets from LKB1-deficient T~reg~ cells ([Extended Data Fig. 10a](#F14){ref-type="fig"}). Activated WT T~reg~ cells upregulated the expression of β-catenin, a key mediator of Wnt signaling, while the induction was attenuated in LKB1-deficient T~reg~ cells ([Fig. 4g](#F4){ref-type="fig"}). Aside from the modestly reduced β-catenin (*Ctnnb1*) mRNA ([Extended Data Fig. 10b](#F14){ref-type="fig"}), LKB1-deficient T~reg~ cells had increased phosphorylation of β-catenin that mediates its degradation ([Extended Data Fig. 10c](#F14){ref-type="fig"}). Moreover, β-catenin bound to a T-cell factor 3 (TCF3) motif in the *Pdcd1* locus in WT T~reg~ cells, but this binding was lost in LKB1-deficient T~reg~ cells ([Extended Data Fig. 10d](#F14){ref-type="fig"}). Expression of constitutively active β-catenin by retrovirus (β-cat-RV) restored the aberrant expression of PD-1 and GITR on LKB1-deficient T~reg~ cells ([Fig. 4h](#F4){ref-type="fig"} and [Extended Data Fig. 10e](#F14){ref-type="fig"}), but did not affect CD25 expression ([Extended Data Fig. 10e](#F14){ref-type="fig"}) or survival of T~reg~ cells (data not shown). Similar rescue effects were observed in β-catenin-expressing T~reg~ cells after acute deletion of LKB1 ([Extended Data Fig. 10f](#F14){ref-type="fig"}). Moreover, β-cat-RV substantially rectified the defects of LKB1-deficient T~reg~ cells in suppressing DC expression of PD-L2, CD80 and CD86 ([Extended Data Fig. 10g](#F14){ref-type="fig"}) and T~H~2 cell differentiation polarized by TSLP-DCs ([Fig. 4i](#F4){ref-type="fig"}). Collectively, these results indicate an important role of the LKB1-β-catenin axis in the control of T~H~2 responses through modulating PD-1 and T~reg~ cell signature molecules.

Emerging studies highlight the importance of metabolic reprogramming in immune cell activation and differentiation^[@R26]^, but how metabolism and immune function are integrated and especially homeostatic control mechanisms remain poorly defined. Here we identify LKB1 as a crucial checkpoint to maintain T~reg~ cell survival and function through coordinating metabolic and functional fitness of T~reg~ cells ([Extended Data Fig. 10h](#F14){ref-type="fig"}). LKB1 connects immunological signals and cellular metabolism especially mitochondrion-related functions. Furthermore, LKB1 curtails the aberrant induction of PD-1, GITR and OX40 in a β-catenin dependent manner, and blockade of PD-1 signaling reinvigorates the ability of LKB1-deficient T~reg~ cells in the repression of T~H~2 responses. PD-1 upregulation and metabolic alteration have long been observed in exhausted CD8^+^ T cells^[@R27]^, and increasing eveidence reveals the interplay between immune checkpoints and cell metabolism^[@R28]--[@R30]^. Our results suggest that T~reg~ cells not only exist at a resting or activated state^[@R1]^, but could also undergo functional exhaustion. Given the constitutive expression of the epithelial cytokine TSLP and the ensuing stimulation of DCs at the environmental interface, T~reg~ cells require LKB1 to actively maintain their metabolic and immunological homoeostasis, the loss of which results in the apoptotic and functional exhaustion of T~reg~ cells. Our findings point to a previously unrecognized mechanism enforcing homeostatic control of T~reg~ cells, and provide a framework to further understand integration of metabolic signaling and lymphocyte fate and state.

Methods {#S1}
=======

Mice {#S2}
----

C57BL/6, CD45.1^+^, *Stk11*^fl/fl^, *Bcl2l11*^fl/fl^, *Hif1a*^fl/fl^, *Prkaa1*^fl/fl^*, Prkaa2*^fl/fl^, *Rag1*^−/−^*, Il4*^−/−^, *Pdcd1*^−/−^, and *ROSA26*^YFP^ reporter (a loxP-site-flanked STOP cassette followed by the YFP-encoding sequence inserted into the *ROSA26* locus) mice were purchased from the Jackson Laboratory. *Foxp3*^YFP-Cre^ and *Foxp3*^Cre-ERT2^ mice were gifts from A. Rudensky^[@R6],[@R14]^. *Foxp3*^Cre^*Stk11*^fl/fl^ mice were used at 3--5 weeks old unless otherwise noted, with the age and gender-matched WT mice containing the *Foxp3*^Cre^ allele as controls. Other mice were used at 8--10 weeks old unless otherwise noted. BM chimeras were generated by transferring 1 × 10^7^ T cell-depleted BM cells into sub-lethally irradiated (5.5 Gy) *Rag1*^−/−^ mice, followed by reconstitution for at least 2 months. For tamoxifen administration, mice were injected intraperitoneally with tamoxifen (2 mg per mouse) in corn oil every other day for 6 times, and then analyzed 6--7 days after the last injection (unless otherwise noted). All mice were kept in a specific pathogen-free facility in the Animal Resource Center at St. Jude Children's Research Hospital, and animal protocols were approved by the Institutional Animal Care and Use Committee.

Flow cytometry {#S3}
--------------

For analysis of surface markers, cells were stained in PBS containing 2% (wt/vol) BSA, with anti-CD4 (RM4-5), anti-CD8α (53--6.7), anti-TCRβ (H57-597), anti-CD25 (PC61.5), anti-CD44 (1M7), anti-CD62L (MEL-14), anti-CD45.1 (A20), anti-CD45.2 (104), anti-ICOS (C398.4A), anti-GITR (DTA-1), anti-OX40 (OX-86), anti-PD-1 (J43), anti-MHC-II (M5/114.15.2), anti-CD11b (M1/70), anti-PD-L2 (122), anti-CD11c (N418), anti-Ly6G (RB6-8C5; all from eBioscience), anti-Siglec-F (E50-2440; BD Biosciences), and anti-F4/80 (BM8; BioLegend). Intracellular Foxp3 (FJK-16s), GATA3 (TWAJ), IRF4 (3E4), RORγt (AFKJS-9), IFN-γ (XMG1.2), IL-4 (11B11), IL-5 (TRFK5), IL-13 (eBio13A), IL-17 (17B7; all from eBioscience); T-bet (4B10), CTLA-4 (UC10-4B9; BioLegend), and Bim (C34C5; Cell Signaling Technology) were analyzed by flow cytometry according to the manufacturer's instructions. For detection of phosphorylated signaling proteins, lymphocytes were rested in complete medium for 1 h. They were fixed with Phosflow Lyse/Fix buffer, followed by permeabilization with Phosflow Perm buffer III (BD Biosciences) and staining with antibodies to S6 phosphorylated at Ser 235 and Ser 236 (D57.2.2E; Cell Signaling Technology), 4E-BP1 phosphorylated at Thr 37 and Thr 46 (236B4; Cell Signaling Technology). For intracellular cytokine staining, T cells were stimulated for 4 h with PMA plus ionomycin in the presence of monensin before being stained according to the manufacturer's instructions (eBioscience). BrdU and active caspase-3 staining was performed according to the manufacturer's instruction (BD Biosciences). For measurement of mitochondrial mass, potential and ROS, T~reg~ cells were incubated for 30 min at 37°C with 10 nM MitoTracker Deep Red (Life Technologies), 20 nM TMRM (tetramethyl rhodamine, methyl ester; ImmunoChemistry Technologies) or 5 μM MitoSOX Red (Life Technologies), before staining surface markers. Neutral lipid droplets in T~reg~ cells were stained with HCS LipidTOX^™^ Deep Red Neutral Lipid Stain according to the manufacturer's instruction (ThermoFisher Scientific). Flow cytometry data were acquired on LSRII or LSR Fortessa (BD Biosciences) and analyzed using Flowjo software (Tree Star).

Cell purification and culture {#S4}
-----------------------------

Naïve CD4^+^ T cells (CD4^+^CD62L^+^CD44^lo^CD25^−^) and splenic DCs (Lin^−^CD11c^+^MHC-II^+^) from C57BL/6 mice and T~reg~ cells (CD4^+^YFP^+^) from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice were sorted on a MoFlow (Beckman-Coulter) or Reflection (i-Cyt). Naïve CD4^+^ T cells, DCs, and T~reg~ cells were cultured in Click's medium (plus β-mercaptoethanol) supplemented with 10% (vol/vol) FBS and 1% (vol/vol) penicillin-streptomycin. For cell activation, T~reg~ cells were activated with plate-coated anti-CD3 (5 μg/ml; 2C11; Bio X Cell) and anti-CD28 (5 μg/ml; 37.51; Bio X Cell) for the indicated time points. For T cell differentiation *in vitro*, splenic DCs from C57BL/6 mice were stimulated with TSLP^[@R31]^ (10 ng/ml) or LPS (50 ng/ml) for 18 h, and then washed with HBSS containing 2% FBS twice before coculturing with naïve CD4^+^ T cells and T~reg~ cells in the presence of 1 μg/ml CD3 antibody for additional 5 days. To block PD-1 signaling, control IgG (30 μg/ml) or mixture of blocking antibodies against PD-1 (10 μg/ml; J43; eBioscience), PD-L1 (10 μg/ml; MIH5; eBioscience), and PD-L2 (10 μg/ml; TY25; eBioscience) were added. At the end of culture, viable cells were purified using Ficoll and stimulated for 4 h with PMA plus ionomycin in the presence of monensin before intracellular staining of cytokines. Constitutively active β-catenin constructs^[@R32]^ were generated by PCR and cloned into the mouse stem cell virus retroviral vector. Retroviral packaging and transduction were performed as described previously^[@R33]^.

RNA and immunoblot analysis {#S5}
---------------------------

Real-time PCR analysis was performed with probe sets *Stk11* (Mm00488473_g1), *Hdc* (Mm00456104_m1), *Ctnnb1* (Mm00483039_m1), and *Actb* (Mm00607939_s1) (all from ThermoFisher Scientific). Immunoblots were performed and quantified as described previously^[@R34]^, using the following antibodies: phospho-LKB1 (Ser428; C67A3), LKB1 (D60C5), β-catenin (D10A8), phospho-β-catenin (Ser33/37/Thr41), phospho-S6 (Ser235/236; D57.2.2E), phospho-AKT (Ser473; D9E), phospho-FOXO1 (Ser256), phospho-AMPK (Thr172) (all from Cell Signaling Technology), and β-ACTIN (Sigma).

Metabolomics analysis {#S6}
---------------------

T~reg~ cells from *Foxp3*^Cre^*Stk11*^fl/+^ and *Foxp3*^Cre^*Stk11*^fl/fl^ mice (approximately 16 days old) were activated with plate-coated anti-CD3 (5 μg/ml) and anti-CD28 (5 μg/ml) for 48 h, followed by extensive wash with PBS. Metabolites were extracted from cell pellets and culture medium using 80% methanol containing 0.05 ng/μl inosine-15N4 and 0.05 ng/μl thymine-d4 as internal standards (Cambridge Isotope Laboratories, Inc., Tewksbury MA). The samples were centrifuged (10 min, 9,000 × g, 4ºC) and the supernatants were collected. Three liquid chromatography tandem mass spectrometry (LC-MS) profile metabolites. Negative ion, targeted profiling of polar metabolites was performed using an ACQUITY UPLC (Waters Corp, Milford MA) coupled to a 5500 QTRAP triple quadrupole mass spectrometer (AB SCIEX, Framingham MA). Extracts (10 μl) were injected directly onto a 150 × 2.0 mm Luna NH2 column (Phenomenex, Torrance CA). The column was eluted at a flow rate of 400 μl/min with initial conditions of 10% mobile phase A (20 mM ammonium acetate and 20 mM ammonium hydroxide (Sigma-Aldrich) in water (VWR)) and 90% mobile phase B (10 mM ammonium hydroxide in 75:25 v/v acetonitrile/methanol (VWR)) followed by a 10 min linear gradient to 100% mobile phase A. The ion spray voltage was -4.5 kV and the source temperature was 500°C. Positive ionization mode profiling of polar metabolites was performed using a Nexera X2 U-HPLC (Shimadzu, Marlborough, MA)-Q Exactive Orbitrap (Thermo Fisher Scientific; Waltham, MA) LC-MS system. The 80% methanol extracts (100 μl) were dried using a nitrogen evaporator (TurboVap LV; Biotage) and then resuspended in 10 μl of water and 90 μl of 74.9:24.9:0.2 vol/vol/vol acetonitrile/methanol/formic acid containing stable isotope-labeled internal standards (valine-d8, Isotec; and phenylalanine-d8, Cambridge Isotope Laboratories; Andover, MA). The samples were centrifuged (10 min, 9,000 × g, 4°C) and the supernatants were injected directly onto a 150 × 2 mm Atlantis HILIC column (Waters; Milford, MA). The column was eluted isocratically at a flow rate of 250 μl/min with 5% mobile phase A (10 mM ammonium formate and 0.1% formic acid in water) for 1 min followed by a linear gradient to 40% mobile phase B (acetonitrile with 0.1% formic acid) over 10 min. The electrospray ionization voltage was 3.5 kV and data were acquired using full scan analysis over m/z 70--800 at 70,000 resolution. Reversed-phase C18 chromatography/negative ion mode MS analyses of free fatty acids and bile acids were conducted using an LC-MS system comprised of a Shimadzu Nexera X2 U-HPLC (Shimadzu Corp.; Marlborough, MA) coupled to a Q Exactive hybrid quadrupole orbitrap mass spectrometer (Thermo Fisher Scientific; Waltham, MA). Medium (30 μl) was extracted using 90 μl of methanol containing PGE2-d4 (Cayman Chemical Co.; Ann Arbor, MI) and centrifuged (10 min, 9,000 × g, 4°C) and the cell extracts were analyzed directly. The samples were injected onto a 150 × 2.1 mm ACQUITY BEH C18 column (Waters; Milford, MA). The column was eluted isocratically at a flow rate of 450 μl/min with 80% mobile phase A (0.01% formic acid in water) for 3 min followed by a linear gradient to 100% mobile phase B (acetonitrile with 0.01% acetic acid) over 12 min. MS analyses were carried out in the negative ion mode using electrospray ionization, full scan MS acquisition over 70--850 m/z, and a resolution setting of 70,000. Metabolite identities were confirmed using authentic reference standards. Other MS settings were: spray voltage −3.5 kV, capillary temperature 320°C, and heater temperature 300°C. LC-MS data were processed and visually inspected using MultiQuant 2.1 (SCIEX; Framingham, MA) and TraceFinder 3.1 software (Thermo Fisher Scientific; Waltham, MA). Metabolite set enrichment analysis was performed as described previously^[@R35]^.

Metabolic assays {#S7}
----------------

T~reg~ cells were stimulated with plate-bound α-CD3-CD28 for 48 h. To measure *de novo* lipid synthesis, D-\[1-^14^C\] glucose (Perkin Elmer) was added to the cells for the final 8 h of culture. Cells were lysed in 0.5% Triton X-100, and the lipid fraction was extracted by addition of chloroform and methanol (2:1 v/v) with vortexing, followed by addition of water with vortexing. After centrifugation, the lipid-containing phase was obtained and ^14^C incorporation was measured with a Beckman LS6500 scintillation counter. OCR and ECAR were measured in XF media (non-buffered DMEM containing 5 mM glucose, 2 mM L-glutamine and 1 mM sodium pyruvate), under basal conditions and in response to 1 μM oligomycin, 2 μM fluoro-carbonyl cyanide phenylhydrazone (FCCP), 200 μM Etomoxir (Eto) and 1 μM Rotenone/antimycin A (Rot/AA) using the XF-24 Extracellular Flux Analyzer (Seahorse Bioscience). Intracellular levels of ATP in T~reg~ cells were measured using luminescent ATP detection assay kit (Abcam).

Gene expression profiling {#S8}
-------------------------

RNA samples from donor-derived T~reg~ cells from CD45.1^+^:WT and CD45.1^+^:*Foxp3*^Cre^*Stk11*^fl/fl^ mixed BM chimeras (*n* = 5 each group) were analyzed using the Mouse Gene 2.0 ST Signals array. Differentially expressed transcripts were identified by ANOVA (Partek Genomics Suit 6.5), and the Benjamini-Hochberg method was used to estimate the false discovery rate (FDR). Gene set enrichment analysis (GSEA) was performed as described previously^[@R36]^. The microarray data have been deposited in the Gene Expression Omnibus under accession number GSE83088.

Serum antibodies {#S9}
----------------

Immunoglobulin subclasses were measured with kits from Alpha Diagnostic International (5110) and Millipore (MGAMMAG-300K), respectively^[@R36]^.

OVA-induced allergic airway inflammation {#S10}
----------------------------------------

Mice were sensitized with mixture of OVA (50 μg/ml per mouse) and alum adjuvant (1:2 dilution) injected intraperitoneally (100 μl per mouse), followed by the second sensitization 12 days later. Eight days after the second sensitization, mice were intranasally challenged with OVA for 4 consecutive days. At 18 h after the last challenge, lymphocytes were isolated from the spleen and lung and analyzed by flow cytometry.

Chromatin immunoprecipitation (ChIP) {#S11}
------------------------------------

ChIP methodology was performed as described^[@R37],[@R38]^. Briefly, cells were cross-linked for 40 min using 12.5 μM ethylene glycol-bis(succinimidyl succinate) (ThermoFisherScientific), followed by the addition of formaldehyde (1% final concentration) and incubation for additional 20 min. After the reactions were quenched with glycine, cell pellets were lysed in cell lysis buffer (25 mM HEPES pH 7.8, 1.5 mM MgCl~2~, 10 mM KCl, 0.3% NP-40 and 1 mM DTT) containing a protease inhibitor tablet (Roche) for 10 min on ice. Nuclei were pelleted and lysed in nuclear lysis buffer (50 mM HEPES, pH 7.9, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-deoxycholate, 0.2% SDS) containing a protease inhibitor tablet for 10 min on ice, prior to sonication into 500 bp pieces using a Diagenode Bioruptor. Sheared chromatin was cleared of debris and incubated with IgG (Santa Cruz) or anti-β-catenin antibody (Cell Signaling; 1:50) and blocker (Active Motif) rotating overnight at 4ºC. Chromatin immunoprecipitation and subsequent DNA purification were performed using the ChIP-IT High Sensitivity Kit (Active Motif) per manufacturer's instructions. Realtime PCRs were performed using the primers spanning the TCF3 motif in the *Pdcd1* locus (<http://rstats.immgen.org/Chromatin/chromatin.html>): F-GGAAACAGGCACCAAGACAT, R-CTACTCAATCCGTGGGAGGA, and negative control primer sets (Active Motif \#71011). Data analysis was performed using the 'Percent Input' normalization method.

Statistical analysis {#S12}
--------------------

*P* values were calculated by Mann-Whitney test, two-tailed unpaired Student's *t* test, one-way ANOVA or two-way ANOVA as indicated using GraphPad Prism, unless otherwise noted. Statistical analysis of mouse survival and respective *P* values were determined using the Logrank test. *P* \< 0.05 was considered as significant. All error bars represent the s.e.m.

Data availability {#S13}
-----------------

The microarray data that support the findings of this study have been deposited in the Gene Expression Omnibus under accession number GSE83088.

Extended Data {#S14}
=============

![Disrupted immune homeostasis in *Foxp3*^Cre^*Stk11*^fl/fl^ mice\
**a**, Expression of *Stk11* mRNA and LKB1 protein in CD4^+^YFP^+^ T cells (T~reg~ cells) from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice. **b**, Representative images of hematoxylin and eosin staining of colon (original magnification, ×20) and cecum (×10) from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice. **c**, Representative images of MCPT1 (mast cell protease 1) staining of colon (original magnification, ×20) and cecum (×20) from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice. MCPT1 (brown) labels the interepithelial mucosal mast cells (ieMMCs). **d**, Quantification of serum MCP-1 (WT *n* = 10; *Foxp3*^Cre^*Stk11*^fl/fl^ *n* = 12), TNF-α (WT *n* = 11; *Foxp3*^Cre^*Stk11*^fl/fl^ *n* = 12) and IFN-γ (WT *n* = 9; *Foxp3*^Cre^*Stk11*^fl/fl^ *n* = 8). **e**, Quantification of IgG2a/c, IgG2b, IgA and IgM in the serum from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice (*n* = 6 each group). **f**, **g**, Flow cytometry of eosinophils (CD11b^+^Siglec-F^+^) in the spleen (**f**) and lung (**g**), and alveolar macrophages (CD11b^−^Siglec-F^+^) in the lung (**g**) from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice. **h**, **i**, Flow cytometry of neutrophils (CD11b^+^Ly6G^+^, **h**) and macrophages (CD11b^+^F4/80^+^, **i**) in the spleen from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice. **j**, **k**, Representative images of MBP (major basic protein, pink, which labels eosinophils) (**j**) and YM1 (brown, which labels M2 macrophages) (**k**) staining of skin (×20) from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice. Data are representative of two (**a--c, j**, **k**), one (**d**, **e**) or at least three (**f--i**) independent experiments. Data are mean ± s.e.m. *P* values are determined by two-tailed Student's *t*-test (**d**, **e**). NS, not significant; **\****P* \< 0.05, \*\**P* \< 0.005, \*\*\**P* \< 0.0005. Numbers in gates indicate percentage of cells.](nihms894686f5){#F5}

![Excessive T cell activation and T~H~2-dominant inflammatory responses in *Foxp3*^Cre^*Stk11*^fl/fl^ mice\
**a**, Expression of CD62L and CD44 on CD4^+^ and CD8^+^ T cells in the spleen from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice. **b**, Flow cytometry and quantification of IL-4- and IL-5-producing CD4^+^ T cells in the spleen from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice (approximately 4--5 weeks old) after *in vitro* stimulation for 4 h. **c**, Flow cytometry of IL-4- and IL-5-producing T~reg~ cells in the spleen from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice. **d**, **e**, Flow cytometry and quantification of IFN-γ-(**d**) and IL-17-producing (**e**) CD4^+^ T cells in the spleen from the mice in (**b). f**, Flow cytometry of IL-4-producing CD4^+^ T cells in the lung (left panel) and colon (right panel) from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice. **g**, Expression of IL-5 and IL-17 in CD4^+^ T cells in the spleen from young WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice (approximately 16 days old). Right, fold changes of IL-5- or IL-17-producing CD4^+^ T cells from *Foxp3*^Cre^*Stk11*^fl/fl^ versus WT counterparts (*n* = 5 each group). Data are representative of at least three (**a**--**g**) independent experiments. Data are mean ± s.e.m. *P* values are determined by Mann-Whitney test (**b**, **d**, **e**) or two-tailed Student's *t*-test (**g**). \**P* \< 0.05, \*\**P* \< 0.005, \*\*\**P* \< 0.0005. Numbers in quadrants or gates indicate percentage of cells.](nihms894686f6){#F6}

![LKB1 regulates T~reg~ cell homeostasis and function\
**a**, Flow cytometry of T~reg~ cells in the lung (left panel) and colon (right panel) from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice. **b**, BrdU incorporation in splenic T~reg~ cells from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice at 16 h after injection of BrdU. **c**, **d**, Expression of active caspase-3 (**c**) and Bim (**d**) in CD45.2^+^ T~reg~ cells from CD45.1^+^:WT and CD45.1^+^:*Foxp3*^Cre^*Stk11*^fl/fl^ mixed BM chimeras. **e**, Flow cytometry of splenic T~reg~ cells from young WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice (approximately 16 days old). Right, proportions of T~reg~ cells (WT *n* = 7; *Foxp3*^Cre^*Stk11*^fl/fl^ *n* = 5). **f**, **g**, Expression of Bim (**f**), and CD62L and CD44 (**g**) in splenic CD4^+^ T cells from young WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice (approximately 16 days old). **h**, **i**, Representative images of hematoxylin and eosin staining of the lung (**h**) and measurement of IgE in the serum (**i**) from young WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice (approximately 16 days old). **j**, Flow cytometry of splenic T~reg~ cells from WT, *Foxp3*^Cre^*Stk11*^fl/fl^ and *Foxp3*^Cre^*Stk11*^fl/fl^*Bcl2l11*^fl/fl^ mice. **k**, Expression of CD62L and CD44 on CD4^+^ T cells from WT, *Foxp3*^Cre^*Stk11*^fl/fl^ and *Foxp3*^Cre^*Stk11*^fl/fl^*Bcl2l11*^fl/fl^ mice. **l**, Flow cytometry of splenic T~reg~ cells from WT and *Foxp3*^Cre^*Bcl2l11*^fl/fl^ mice. **m**, Expression of IL-4 and IFN-γ in CD4^+^ T cells from WT and *Foxp3*^Cre^*Bcl2l11*^fl/fl^ mice after *in vitro* stimulation for 4 h. Data are representative of at least three (**a**--**d**) or two (**e**--**m**) independent experiments. Data are mean ± s.e.m. *P* values are determined by Mann-Whitney test (**e**) or two-tailed Student's *t*-test (**i**). NS, not significant; \**P* \< 0.01. Numbers above graphs indicate the mean fluorescence intensity; numbers in quadrants or gates indicate percentage of cells.](nihms894686f7){#F7}

![LKB1 regulates the expression of distinct T~reg~ signature molecules\
**a**, Comparison of PD-1, GITR and OX40 expression on T~reg~ cells from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice. **b**, Flow cytometry of resting (CD62L^hi^CD44^low^) and activated (CD62L^low^CD44^hi^) T~reg~ cells in the spleen from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice. **c**, Comparison of GATA3, IRF4, T-bet and RORγt in T~reg~ cells from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice. **d**, Comparison of Foxp3, ICOS, CTLA-4 and CD25 expression in T~reg~ cells from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice. **e**, Comparison of Foxp3, ICOS, CTLA-4 and CD25 expression in CD45.2^+^ WT and CD45.2^+^ *Foxp3*^Cre^*Stk11*^fl/fl^ T~reg~ cells from mixed BM chimeras. **f**, Expression of *Stk11* mRNA in CD4^+^Foxp3-GFP^+^YFP^+^ T cells from *Foxp3*^Cre-ERT2^*Stk11*^fl/+^ and *Foxp3*^Cre-ERT2^*Stk11*^fl/fl^ mice. **g**, Flow cytometry of Foxp3-GFP^+^YFP^+^ T~reg~ cells from *Foxp3*^Cre-ERT2^*Stk11*^fl/+^ and *Foxp3*^Cre-ERT2^*Stk11*^fl/fl^ mice at day 20 after the last tamoxifen administration. **h**, Proportion of DAPI^+^ Foxp3-GFP^+^YFP^+^ T~reg~ cells in (**g**). **i**, Flow cytometry of Foxp3-GFP^+^YFP^+^ T~reg~ cells from *Foxp3*^Cre-ERT2^*Stk11*^fl/+^ and *Foxp3*^Cre-ERT2^*Stk11*^fl/fl^ mice at day 6 after the last tamoxifen administration. **j**, **k**, Expression of IL-4 versus IL-13 (**j**) and IFN-γ versus IL-17 (**k**) in CD4^+^ T cells from *Foxp3*^Cre-ERT2^*Stk11*^fl/+^ and *Foxp3*^Cre-ERT2^*Stk11*^fl/fl^ mice after *in vitro* stimulation for 4 h. **l**, Comparison of Foxp3-GFP, ICOS and CD25 expression on Foxp3-GFP^+^YFP^+^ T~reg~ cells from *Foxp3*^Cre-ERT2^*Stk11*^fl/+^ and *Foxp3*^Cre-ERT2^*Stk11*^fl/fl^ mice. **m**, Flow cytometry of resting (CD62L^hi^CD44^low^) and activated (CD62L^low^CD44^hi^) T~reg~ cells in the spleen from *Foxp3*^Cre-ERT2^*Stk11*^fl/+^ and *Foxp3*^Cre-ERT2^*Stk11*^fl/fl^ mice. Data are representative of at least three (**a**--**i**, **l**, **m**) or two (**j**, **k**) independent experiments. Data are mean ± s.e.m. *P* values are determined by two-tailed Student's *t*-test (**f**). \*\*\**P* \< 0.0001. Numbers above graphs indicate the mean fluorescence intensity; numbers in quadrants or gates indicate percentage of cells.](nihms894686f8){#F8}

![LKB1 regulates T~reg~ cell function independently of mTOR-HIF-1α axis and AMPK signaling\
**a**, **b**, Phosphorylation of S6 (**a**), and phosphorylation of AKT S473 and FOXO1 (**b**) in WT and *Foxp3*^Cre^*Stk11*^fl/fl^ T~reg~ cells stimulated with or without α-CD3-CD28 for 48 h. **c**, Flow cytometry of splenic T~reg~ cells from WT, *Foxp3*^Cre^*Stk11*^fl/fl^, *Foxp3*^Cre^*Hif1a*^fl/fl^ and *Foxp3*^Cre^*Stk11*^fl/fl^*Hif1a*^fl/fl^ mice. **d**, Expression of CD62L and CD44 on CD4^+^ T cells from the mice in (**c**). **e**, Expression of IL-4 and IL-17 in CD4^+^ T cells from the mice in (**c**) after *in vitro* stimulation for 4 h. **f**, Phosphorylation of AMPK in WT and LKB1-deficient T~reg~ cells stimulated with α-CD3-CD28 for 48 h. **g**, Expression of CD62L and CD44 on CD4^+^ (upper) and CD8^+^ T cells (lower) from WT and *Foxp3*^Cre^*Prkaa1*^fl/fl^*Prkaa2*^fl/fl^ mice. **h**, Expression of IFN-γ, IL-4 and IL-17 in CD4^+^ (upper) and CD8^+^ T cells (lower) from WT and *Foxp3*^Cre^*Prkaa1*^fl/fl^*Prkaa2*^fl/fl^ mice after *in vitro* stimulation for 4 h. Data are representative of two (**a**--**f**) or three (**g**, **h**) independent experiments. Numbers in quadrants or gates indicate percentage of cells.](nihms894686f9){#F9}

![LKB1-dependent gene expresison and metabolic programs in T~reg~ cells\
**a**, Gene set enrichment analysis (GSEA) of transcriptional profiles in WT and *Foxp3*^Cre^*Stk11*^fl/fl^ T~reg~ cells from mixed BM chimeras (*n* = 5 each group). The list of top 10 gene sets downregulated in *Foxp3*^Cre^*Stk11*^fl/fl^ T~reg~ cells were shown. NES, normalized enrichment score. **b**, **c**, The gene sets of TCA cycle and respiratory electron transport (**b**) and mitochondrial protein import (**c**) were enriched among the top 10 downregulated pathways in *Foxp3*^Cre^*Stk11*^fl/fl^ T~reg~ cells. **d**, Heat maps showing relative abundance of metabolites differentially expressed and unsupervised hierarchical clustering. **e**, **f**, Relative abundance of metabolites implicated in TCA cycle (**e**) or glycolytic pathways (**f**) in *Foxp3*^Cre^*Stk11*^fl/+^ and *Foxp3*^Cre^*Stk11*^fl/fl^ T~reg~ cells. DHAP: glyceraldehyde 3P; PEP: phosphoenolpyruvic acid. **g**, Comparison of mitochondrial mass, TMRM (indicative of mitochondrial membrane potential) and ROS production in WT and LKB1-deficient T~reg~ cells. **h**, Relative amount of intracellular ATP in WT and LKB1-deficient T~reg~ cells. **i**, **j**, Oxygen consumption rate (OCR) (**i**) and extracellular acidification rate (ECAR) (**j**) of activated Foxp3-GFP^+^YFP^+^ T~reg~ cells from *Foxp3*^Cre-ERT2^*Stk11*^fl/+^ and *Foxp3*^Cre-ERT2^*Stk11*^fl/fl^ mice. **k**, Comparison of lipid droplets in WT and LKB1-deficient T~reg~ cells. **l**, OCR of activated Foxp3-GFP^+^YFP^+^ T~reg~ cells responding to the treatment of inhibitors Oligomycin (Oligo), FCCP, etomoxir (Eto) and Rotenone/antimycin A (Rot/AA). **m**, *De novo* lipid biosynthesis of Foxp3-GFP^+^YFP^+^ T~reg~ cells stimulated with α-CD3-CD28 for 48 h. Data are representative of one (**a**--**c**; *n* = 5 mice each group; **d**--**f**; *Foxp3*^Cre^*Stk11*^fl/+^ *n* = 3, *Foxp3*^Cre^*Stk11*^fl/fl^ *n* = 4) or two (**g**--**m**) independent experiments. Data are mean ± s.e.m. *P* values are determined by two-tailed Student's *t*-test (**e**, **f**, **h**--**j**, **m**) or two-way ANOVA (**l**). NS, not significant; \**P* \< 0.05, \*\**P* \< 0.005. Numbers above graphs indicate the mean fluorescence intensity.](nihms894686f10){#F10}

![Deletion of IL-4 partially rescues dysregulated type 2 immune responses, but not T~reg~ cell function or overall immune homeostasis\
**a**, **b**, Expression of IL-4 and IL-13 (**a**) and IL-5 (**b**) in splenic CD4^+^ T cells from WT, *Foxp3*^Cre^*Stk11*^fl/fl^, *Il4*^−/−^ and *Foxp3*^Cre^*Stk11*^fl/fl^*Il4*^−/−^ mice after *in vitro* stimulation for 4 h. **c**, **d**, Flow cytometry of eosinophils (CD11b^+^Siglec-F^+^) (**c**) and CD11b^+^PD-L2^+^ DCs (gated on CD11c^+^MHC-II^+^) (**d**) in the spleen from the mice in (**a**). **e**, Quantification of IgE and IgG1 in the serum from the mice in (**a**, *n* = 3 each group). **f**, Flow cytometry of splenic T~reg~ cells from the mice in (**a**). **g**, Mean fluorescence intensity (MFI) of PD-1, GITR and OX40 expression on T~reg~ cells from the mice in (**a**). **h**, Expression of CD62L and CD44 on splenic CD4^+^ T cells from the mice in (**a**). **i**, Expression of IFN-γ and IL-4 in splenic CD4^+^ T cells from the mice in (**a**) after *in vitro* stimulation for 4 h. **j**, Representative images of hematoxylin and eosin staining of the lung (original magnification, ×10), liver (×10) and skin (×20) from the mice in (**a**). Data are representative of at least three (**a**--**d**, **f**, **h**, **i**) or two (**e**, **g**, **j**) independent experiments. Data are mean ± s.e.m. *P* values are determined by one-way ANOVA (**e**, **g**). NS, not significant; \**P* \< 0.05, \*\**P* \< 0.005. Numbers in quadrants or gates indicate percentage of cells.](nihms894686f11){#F11}

![Defects of LKB1-deficient T~reg~ cells in suppressing DC maturation and T~H~2 cell differentiation\
**a**, Production of IL-25 and IL-33 in the homogenate of the lung from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice, normalized by the weight of the lung (WT, *n* = 7; *Foxp3*^Cre^*Stk11*^fl/fl^, *n* = 5). **b**, Fold change of CD80 and CD86 expression on splenic DCs from C57BL/6 mice stimulated with TSLP for 18 h. **c**, Mean fluorescence intensity (MFI) of CD80 and CD86 expression on DCs (with or without TSLP) cultured alone, or together with WT or *Foxp3*^Cre^*Stk11*^fl/fl^ T~reg~ cells for 48 h. **d**, Naïve CD4^+^ T cells were cocultured with TSLP-DCs alone, or together with T~reg~ cells from *Foxp3*^Cre-ERT2^*Stk11*^fl/+^ or *Foxp3*^Cre-ERT2^*Stk11*^fl/fl^ mice (after tamoxifen treatment) for 5 days, and expression of *Il4*, *Il5* and *Il13* mRNA in cocultured CD4^+^ T cells was measured after restimulation with α-CD3 for 5 h. **e**, **f**, Naïve CD4^+^ T cells were cocultured with LPS-primed DCs alone, or together with T~reg~ cells from *Foxp3*^Cre-ERT2^*Stk11*^fl/+^ or *Foxp3*^Cre-ERT2^*Stk11*^fl/fl^ mice (after tamoxifen treatment) for 5 days, followed by analyses of IFN-γ expression after *in vitro* stimulation for 4 h (**e**), and *Ifng* mRNA expression after restimulation with α-CD3 for 5 h (**f**). Data are representative of two (**a**, **d**--**f**) or three (**b**, **c**) independent experiments. Data are mean ± s.e.m. *P* values are determined by two-tailed Student's *t*-test (**a**, **b**) or one-way ANOVA (**c**). NS, not significant; \**P* \< 0.05, \*\**P* \< 0.005. Numbers in gates indicate percentage of cells.](nihms894686f12){#F12}

![Appropriate control of PD-1 expression is important for T~reg~ cells in suppressing T~H~2 immune responses\
**a**, **b**, Fold change of PD-1, GITR and OX40 expression on lung T~reg~ cells (**a**), or splenic T~reg~ cells (**b**) from OVA-sensitized C57BL/6 mice with or without OVA inhalation challenge. **c**, Expression of IL-4 in CD4^+^ T cells cocultured with TSLP-DCs, or together with T~reg~ cells transduced with control retrovirus (RV) or PD-1-expressing retrovirus (*Pdcd1*-RV). **d**, Expression of IL-4 in CD4^+^ T cells cocultured with TSLP-DCs, or together with WT or PD-1-deficient T~reg~ cells. **e**, Flow cytometry of eosinophils (CD11b^+^Siglec-F^+^) in the lung and spleen from *Rag1*^−/−^ mice reconstituted with Scurfy:WT or Scurfy:*Pdcd1*^−/−^ BM cells. **f**, Concentration of IgG1 and IgG2a/c in the serum from the mice in (**e**). Data are representative of two (**a**--**f**) independent experiments. Data are mean ± s.e.m. *P* values are determined by two-tailed Student's *t*-test (**a**, **b**, **f**). NS, not significant; \**P* \< 0.05, \*\**P* \< 0.005. Numbers in gates indicate percentage of cells.](nihms894686f13){#F13}

![T~reg~ cells require the LKB1-β-catenin axis to enforce their functional fitness in maintaining immune homeostasis\
**a**, GSEA reveals the significant enrichment of the Wnt signaling gene set among the downregulated pathways in LKB1-deficient T~reg~ cells. **b**, Relative expression of *Ctnnb1* mRNA in activated WT and LKB1-deficient T~reg~ cells. **c**, Expression of total and phosphorylated β-catenin in activated WT and LKB1-deficient T~reg~ cells. Right, relative phosphorylation of β-catenin normalized by total β-catenin. **d**, ChIP and realtime PCR analysis of β-catenin-bound DNA of the *Pdcd1* locus from activated *Foxp3*^Cre-ERT2^*Stk11*^fl/+^ and *Foxp3*^Cre-ERT2^*Stk11*^fl/fl^ T~reg~ cells (following *in vivo* tamoxifen treatment). **e**, Mean fluorescence intensity (MFI) of GITR and CD25 expression on WT and *Foxp3*^Cre^*Stk11*^fl/fl^ T~reg~ cells transduced with control retrovirus (RV) or mutant β-catenin-expressing retrovirus (β-cat-RV). **f**, MFI of PD-1, GITR and CD25 expression on *Foxp3*^Cre-ERT2^*Stk11*^fl/+^ and *Foxp3*^Cre-ERT2^*Stk11*^fl/fl^ T~reg~ cells (following *in vivo* tamoxifen treatment) transduced with control RV or β-cat-RV. **g**, Expression of PD-L2, CD80 and CD86 on DCs cocultured with WT or LKB1-deficient T~reg~ cells transduced with RV or β-cat-RV. Numbers above graphs indicate the MFI. Data are representative of one (**a**) or two (**b**--**g**) independent experiments. Data are mean ± s.e.m. *P* values are determined by two-tailed Student's *t*-test (**d**) or two-way ANOVA (**e**, **f**). NS, not significant; \*\**P* \< 0.005, \*\*\**P* \< 0.0005. **h**, Schematics of LKB1 signaling in the regulation of T~reg~ cell function and immune homeostasis. LKB1 signaling in T~reg~ cells establishes metabolic and homeostatic fitness required for preventing undesired immune responses through selectively controlling the expression of inhibitory regulators, including PD-1, GITR and OX40. Consequently, uncontrolled expression of PD-1 and possible other receptors impairs the capability of T~reg~ cells in suppressing T~H~2 immune responses triggered by TSLP-induced PD-L2^+^ DCs. Although not depicted here, IL-4 contributes to the induction of PD-L2 on DCs and the amplification of T~H~2-mediated immunopathology.](nihms894686f14){#F14}
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![*Foxp3*^Cre^*Stk11*^fl/fl^ mice spontaneously develop a T~H~2-dominant inflammatory disease\
**a**, Survival curve of WT (*n* = 10) and *Foxp3*^Cre^*Stk11*^fl/fl^ mice (*n* = 42; *P* \< 0.0001). **b**, Gross body weight of WT (*n* = 6) and *Foxp3*^Cre^*Stk11*^fl/fl^ mice (*n* = 7). **c**, Representative images of WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice. **d**, **e**, Representative images of the spleen and peripheral lymph nodes (**d**) or hematoxylin and eosin staining of the lung (original magnification, ×10), liver (×10), pancreas (×20), eyelid (×40) and skin (×20) (**e**). **f**, Quantification of serum IL-4 and IL-5 from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice (*n* = 11 each group). **g**, Quantification of serum IgE and IgG1 from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice (*n* = 6 each group). **h**, Expression of IL-4 and IFN-γ in CD4^+^ T cells from young mice (approximately 16 days old). Right, fold changes of IL-4- or IFN-γ-producing CD4^+^ T cells from *Foxp3*^Cre^*Stk11*^fl/fl^ mice versus WT counterparts (*n* = 5 each group). Data are representative of one (**a**), two (**b--g**) or at least three (**h**) independent experiments. Data are mean ± s.e.m. *P* values are determined by Logrank test (**a**), or two-tailed Student's *t*-test (**b, f--h**). \**P* \< 0.05, \*\**P* \< 0.005, \*\*\**P* \< 0.0005. Numbers in quadrants indicate percentage of cells.](nihms894686f1){#F1}

![LKB1 controls T~reg~ cell survival and expression of selective co-receptors PD-1, GITR and OX40\
**a**, T~reg~ cells from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice. Right, proportion and number of T~reg~ cells (WT *n* = 5; *Foxp3*^Cre^*Stk11*^fl/fl^ *n* = 4). **b**, **c**, Caspase-3 activity (**b**) and Bim expression (**c**) in T~reg~ cells. **d**, Donor WT and *Foxp3*^Cre^*Stk11*^fl/fl^ T~reg~ cells from mixed BM chimeras. **e**, IL-4- and IL-17-producing CD4^+^ T cells from the indicated mice. **f**, PD-1, GITR and OX40 expression on T~reg~ cells in **d. g**, PD-1, GITR, OX40, and Bim expression in WT T~reg~ cells and T~reg~ cells with acute deletion of LKB1. Data are representative of at least three (**a**--**g**) independent experiments. Data are mean ± s.e.m. *P* values are determined by Mann-Whitney test (**a**, cell proportion) or two-tailed Student's *t*-test (**a**, cell number). \**P* \< 0.05, \*\**P* \< 0.005. Numbers above graphs indicate the mean fluorescence intensity; numbers in quadrants or gates indicate percentage of cells.](nihms894686f2){#F2}

![LKB1 regulates T~reg~ cell metabolism through connecting immune signals and mitochondrial function\
**a**, Phosphorylation and expression of LKB1 in resting and activated T~reg~ cells. **b**, Phosphorylation of S6 and 4E-BP1 in resting T~reg~ cells. **c**, T~reg~ cells from WT and *Foxp3*^Cre^*Prkaa1*^fl/fl^*Prkaa2*^fl/fl^ mice. **d**, Heat maps of differentially expressed intracellular metabolites and unsupervised hierarchical clustering (*Foxp3*^Cre^*Stk11*^fl/+^ *n* = 3; *Foxp3*^Cre^*Stk11*^fl/fl^ *n* = 4). **e**, Relative abundance of histamine in the cells and culture medium in **d** (*Foxp3*^Cre^*Stk11*^fl/+^ *n* = 3; *Foxp3*^Cre^*Stk11*^fl/fl^ *n* = 4). **f**, *Hdc* mRNA in resting and activated T~reg~ cells. **g**, Metabolite set enrichment of the downregulated and upregulated metabolic pathways in *Foxp3*^Cre^*Stk11*^fl/fl^ T~reg~ cells (false discovery rate, FDR, ≤ 0.05). NES, normalized enrichment score. Data are representative of two (**a**--**c**), one (**d**, **e**, **g**) or three (**f**) independent experiments. Data are mean ± s.e.m. *P* values are determined by two-tailed Student's *t*-test (**e**). \**P* \< 0.01, \*\**P* \< 0.001. Numbers above graphs indicate the mean fluorescence intensity; numbers in gates indicate percentage of cells. For gel source data, see [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}.](nihms894686f3){#F3}

![LKB1-β-catenin axis enforces T~reg~-mediated suppression of T~H~2 responses through the control of PD-1 expression\
**a**, Production of TSLP in the lung (WT *n* = 7; *Foxp3*^Cre^*Stk11*^fl/fl^ *n* = 5). **b**, Fold change of PD-L2 expression on DCs with or without TSLP stimulation (*n* = 3 each group). **c**, CD11b^+^PD-L2^+^ DCs from WT and *Foxp3*^Cre^*Stk11*^fl/fl^ mice. Right, proportion of PD-L2^+^ DCs (*n* = 4 each group). **d**, Mean fluorescence intensity (MFI) of PD-L2 expression on DCs (with TSLP) cultured alone, or together with WT or *Foxp3*^Cre^*Stk11*^fl/fl^ T~reg~ cells (*n* = 4 each group). **e**, Expression of IL-4 and IFN-γ in CD4^+^ T cells cocultured with TSLP-DCs alone, or together with *Foxp3*^Cre-ERT2^*Stk11*^fl/+^ or *Foxp3*^Cre-ERT2^*Stk11*^fl/fl^ T~reg~ cells. **f**, Expression of IL-4 and IFN-γ in CD4^+^ T cells cocultured with TSLP-DCs and *Foxp3*^Cre-ERT2^*Stk11*^fl/+^ or *Foxp3*^Cre-ERT2^*Stk11*^fl/fl^ T~reg~ cells in the presence of control IgG or indicated blocking antibodies. **g**, Phosphorylation of LKB1 and expression of β-catenin in resting and activated T~reg~ cells. **h**, MFI of PD-1 expression on T~reg~ cells transduced with control retrovirus (RV) or mutant β-catenin-expressing retrovirus (β-cat-RV) (*n* = 3 each group). **i**, Expression of IL-4 in CD4^+^ T cells cocultured with TSLP-DCs, or together with RV- or β-cat-RV-transduced T~reg~ cells. Data are representative of at least two (**a**--**i**) independent experiments. Data are mean ± s.e.m. *P* values are determined by two-tailed Student's *t*-test (**a**, **b**), Mann-Whitney test (**c**) or one-way ANOVA (**d**, **h**). NS, not significant; \**P* \< 0.05, \*\**P* \< 0.005. Numbers in quadrants or gates indicate percentage of cells.](nihms894686f4){#F4}

[^1]: Correspondence and requests for materials should be addressed to H.C. (<hongbo.chi@stjude.org>).
